✦ LIBER ✦

EGFR mutations in squamous NSCLC – Prevalence and treatment results with EGFR tyrosine kinase inhibitors (TKIs) in patients from western Slovakia

✍ Scribed by Berzinec, P.; Hlinkova, K.; Copakova, L.; Konecny, M.; Zavodna, K.; Cerna, M.; Culagova, M.; Chowaniecova, G.; Babal, P.

Book ID: 119320852
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 81 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

128PD EGFR, KRAS, PIK3CA MUTATIONS AND R

128PD EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS

✍ Crinò, L.; Pistola, L.; Bianconi, F.; Chiari, R.; Meacci, M.; Colella, R.; Giuff 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB

9162 EGFR, KRAS, PIK3CA mutations and re

9162 EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients

✍ Chiari, R.; Ludovini, V.; Bianconi, F.; Pistola, L.; Colella, R.; Mameli, M.; Gi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

The use of first-generation tyrosine kin

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations

✍ Riely, Gregory J. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

Do We Really Need Another Epidermal Grow

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?

✍ Haspinger, E. R.; Garassino, M. C.; Torri, V.; Cinquini, M.; De Braud, F.; Gelso 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 78 KB

PD-159 Mutation in the tyrosine kinase d

PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

✍ Tsai, C.; Chiu, C.; Chou, T.; Li, L.; Chang, K.; Chen, Y.; Tsai, S.; Perng, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 139 KB